Javascript must be enabled to continue!
c-Jun Transcriptional Regulates NPRL2 to Promote the Proliferation Activity of Prostate Cancer Cells via AKT/MDM2/p53 Signaling Pathway
View through CrossRef
Abstract
BackgroundHigh NPRL2 (Nitrogen permease regulator-like 2) expression is a prognostic marker for poor clinical outcomes in prostate cancer (PCa). However, the regulatory mechanisms of NPRL2 in PCa remain unknown.MethodsThe expression level of NPRL2 in prostate cancer tissues were verified through The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. The effect of NPRL2 gene in promoting the proliferation of prostate cancer was determined by CCK8 and clone formation assays. The apoptosis rate and cell cycle analysis were tested by flow cytometry. Luciferase reporter gene and ChIP were used to verify the binding relationship between transcription factor c-Jun and the NPRL2 5’ region. The effect of NPRL2 and the MK2206 on the AKT/MDM2/p53 signaling pathway was verified by western blotting.ResultsNPRL2 expression level was significantly increased in prostate cancer tissues than normal tissues base on TCGA and GEO database. We investigated that transcription factor c-Jun can bind to the NPRL2 promoter and regulated NPRL2 transcription directly. Then, we revealed that NPRL2 significantly promotes proliferation and reduces apoptosis in PCa cells. Further mechanistic investigations revealed that NPRL2 mediated proliferation promotion effect is associated with the AKT/MDM2/p53 pathway's participation. Besides, CDK2 might serve as an intermediate effector for NPRL2 to regulate the AKT pathway. ConclusionTaken together, our study identified that c-Jun contributes to transcriptional control of NPRL2 and NPRL2 can promote prostate cancer proliferation by activating AKT/MDM2/p53 signaling.
Research Square Platform LLC
Title: c-Jun Transcriptional Regulates NPRL2 to Promote the Proliferation Activity of Prostate Cancer Cells via AKT/MDM2/p53 Signaling Pathway
Description:
Abstract
BackgroundHigh NPRL2 (Nitrogen permease regulator-like 2) expression is a prognostic marker for poor clinical outcomes in prostate cancer (PCa).
However, the regulatory mechanisms of NPRL2 in PCa remain unknown.
MethodsThe expression level of NPRL2 in prostate cancer tissues were verified through The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases.
The effect of NPRL2 gene in promoting the proliferation of prostate cancer was determined by CCK8 and clone formation assays.
The apoptosis rate and cell cycle analysis were tested by flow cytometry.
Luciferase reporter gene and ChIP were used to verify the binding relationship between transcription factor c-Jun and the NPRL2 5’ region.
The effect of NPRL2 and the MK2206 on the AKT/MDM2/p53 signaling pathway was verified by western blotting.
ResultsNPRL2 expression level was significantly increased in prostate cancer tissues than normal tissues base on TCGA and GEO database.
We investigated that transcription factor c-Jun can bind to the NPRL2 promoter and regulated NPRL2 transcription directly.
Then, we revealed that NPRL2 significantly promotes proliferation and reduces apoptosis in PCa cells.
Further mechanistic investigations revealed that NPRL2 mediated proliferation promotion effect is associated with the AKT/MDM2/p53 pathway's participation.
Besides, CDK2 might serve as an intermediate effector for NPRL2 to regulate the AKT pathway.
ConclusionTaken together, our study identified that c-Jun contributes to transcriptional control of NPRL2 and NPRL2 can promote prostate cancer proliferation by activating AKT/MDM2/p53 signaling.
Related Results
Abstract 5120: NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic human NSCLC in a humanized mouse model
Abstract 5120: NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic human NSCLC in a humanized mouse model
Abstract
NPRL2/TUSC4 is a potent tumor suppressor gene whose expression is reduced in many cancers including NSCLC. Restoration of NPRL2 expression in cancer cells i...
Abstract 599: Id4 acts as a tumor suppressor by inducing apoptosis and senescence in p53-dependent manner
Abstract 599: Id4 acts as a tumor suppressor by inducing apoptosis and senescence in p53-dependent manner
Abstract
The physiological mechanisms that can restore biological activity of mutant p53 is an area of high interest given that mutant p53 expression is observed in ...
Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2
Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2
The AP-1 protein complex primarily consists of several proteins from the c-Fos, c-Jun, activating transcription factor (ATF), and Jun dimerization protein (JDP) families. JDP2 has ...
Abstract 1645: Discovery of AMG 232, an inhibitor of the MDM2-p53 interaction: From lead to a clinical candidate
Abstract 1645: Discovery of AMG 232, an inhibitor of the MDM2-p53 interaction: From lead to a clinical candidate
Abstract
The p53 tumor suppressor is controlled by MDM2, which binds p53 and negatively regulates its transcriptional activity and stability. Many tumors overproduce...
Id4 dependent acetylation restores mutant-p53 transcriptional activity
Id4 dependent acetylation restores mutant-p53 transcriptional activity
Abstract
Background
The mechanisms that can restore biological activity of mutant p53 are an area of high interest given that mutant p53 expressi...
Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination
Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination
Abstract
Many mutant p53 proteins exhibit an abnormally long half-life and overall increased abundance compared with wild-type p53 in tumors, contributing to muta...
Data from Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination
Data from Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination
<div>Abstract<p>Many mutant p53 proteins exhibit an abnormally long half-life and overall increased abundance compared with wild-type p53 in tumors, contributing to mut...
Data from Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination
Data from Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination
<div>Abstract<p>Many mutant p53 proteins exhibit an abnormally long half-life and overall increased abundance compared with wild-type p53 in tumors, contributing to mut...

